The disclosure relates to an oral formulation in tablet form, comprising 9-[(2,2-dimethyl-propyl amino)methyl]-minocycline (a tetracycline compound) or a salt thereof, a diluent, a stabilizer, a glidant, a lubricant, and a disintegrant; and an injectable formulation comprising 90-110 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline free base or a salt thereof, one or more components selected from a lyoprotectant, an anti-oxidant, and a pH adjustment compound, and a pharmaceutically acceptable carrier.